Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
This is a list of investigational sleep apnea drugs, or drugs that are currently under development for clinical use in the treatment of sleep apnea but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.
On 26 August 2008, Michael Totten published the report which contained an interview with an expert Patrick Worms who worked in Tbilisi. Worms's version of events was confirmed by an academic Thomas Goltz. Worms said: "The Ossetians start provoking and provoking and provoking by shelling Georgian positions and Georgian villages around there. And it's a classic tit for tat thing. You shell, I shell back. The Georgians offered repeated ceasefires, which the Ossetians broke. (...) On the 6th of August the shelling intensifies from Ossetian positions. And for the first time since the war finished in 1992, they are using 120mm guns. (...) Because of the peace agreement they had, nobody was allowed to have guns bigger than 80mm. Okay, so that's the formal start of the war. It wasn't the attack on Tskhinvali." In August 2008, Peter Roudik, Senior Foreign Law Specialist working for the Library of Congress, criticized Russian claim that the Georgian attack on Tskhinvali was "an act of aggression" and that the aim of Russian intervention was defence against the Georgian forces, saying that only the United Nations Security Council can identify an act of aggression after studying the causes of the military actions. He pointed out that "an act of aggression requires use of the armed forces of a state against the sovereignty, territorial integrity, or political independence of another state," and that South Ossetia was a part of Georgia on 8 August 2008. This reasoning for Russia's action was questionable since there was no "possibility of Georgian aggression against South Ossetia".
Validation activities are conducted to ensure that the resulting products and services meet the requirements for the specified application or intended use. Verification activities are conducted to ensure that the design and development outputs meet the input requirements. It also notes that verification and validation have distinct purposes but can be conducted separately or in any combination, as is suitable for the products and services of the organization. The National Institute of Standards and Technology Information Technology Laboratory Computer Security Resource Center has a variety of definitions for both validation and verification
Sources: en.wikipedia.org
A House of Lords inquiry finds that former speaker Baroness Frances D'Souza broke rules on "personal honour" by writing to Metropolitan Police Commissioner Sir Mark Rowley on Lords headed notepaper to query multiple breaches of the 20 mph speed limit adding up to £400 in fines. 16 October – Liberal Democrat councillors win six council seats at county and borough level in Surrey following a series of by-elections. 17 October – Rupert Lowe, MP for Great Yarmouth and former Reform UK member, is given a seat on the Public Accounts Committee following support from Conservative MPs. 18 October – Conservative MP George Freeman says he has reported a deepfake video depicting him announcing his defection to Reform UK to the police. 19 October – Reform UK's Linden Kemkaran, the leader of Kent County Council, threatens to expose the "cowards" who leaked a video appearing to show her swearing and telling councillors from her party to "suck it up". V-levels are announced by the Department for Education as a new qualification for 16-year-olds. 20 October – Four Reform UK councillors on Kent County Council – Paul Thomas, Oliver Bradshaw, Bill Barret and Maxine Fothergrill – are suspended from the party following leaked video footage of a heated online meeting. Junior minister Claire Hughes reveals she has been diagnosed with breast cancer, and says she will step back from her role while undergoing treatment. Fiona Goddard and Ellie-Ann Reynolds resign from the grooming gang inquiry panel.
Earwigs are not known to purposely climb into external ear canals, though there have been anecdotal reports of earwigs being found in the ear. The name may be a reference to the appearance of their hindwings, which are unique and distinctive among insects, and resemble a human ear when unfolded. Houseflies have an average lifespan of 20 to 30 days, not 24 hours. However, females of the Dolania americana species of mayfly, which do not belong to the group of true flies, have an adult lifespan of as little as 5 minutes. Female praying mantises do not always eat the males during mating. The daddy longlegs spider (Pholcidae) is not the most venomous spider in the world. Their fangs are capable of piercing human skin, but the tiny amount of venom they carry causes only a mild burning sensation for a few seconds. Other species such as harvestmen and crane flies are also called daddy longlegs, and share the misconception of being highly venomous but unable to pierce the skin of humans. People do not swallow large numbers of spiders during sleep. A sleeping person makes noises that warn spiders of danger. Most people also wake up from sleep when they have a spider on their face. Though they are often called "white ants", termites are not ants, nor are they closely related to ants. Termites are actually highly derived cockroaches. Ticks do not jump or fall from trees onto their hosts. Instead, they lie in wait to grasp and climb onto any passing host or otherwise trace down hosts via, for example, olfactory stimuli, the host's body heat, or carbon dioxide in the host's breath.
== Society and culture == In some parts of Africa, including Somalia, Ethiopia and Eritrea, the uvula or a section of it is ritually removed by a traditional healer. In this case, the uvula may be noticeably shortened. It is not thought to contribute to velopharyngeal inadequacy, except in cases where the tonsils have also been removed.
== History == The discovery of coordination polymers, or as later termed metal-organic frameworks, was a logical continuation of research on post-zeolite materials. In 1989 Richard Robson reported the first organic copper-based coordination network by complexation of anions with tetrahedral bridging ligands. Similar copper(I) coordination polymers have been synthesized in 1992 by Susumu Kitagawa, which contained pores with loosely bound acetone molecules, but the structure would collapse upon their removal. Further efforts were devoted to develop extended 3D porous networks that would be stable upon removal of guest molecule and would exhibit permanent porosity. In 1995, Omar M. Yaghi demonstrated interpenetrated 2-D structure with carboxylate-based linkers that remained stable upon guest removal and could re-adsorb specific aromatic molecules. Permanent porosity in 3-D coordination polymer was first demonstrated in 1997 by Susumu Kitagawa. A year later, Yaghi proposed a new synthetical concept that employs secondary building units (SBUs) — metal-carboxylate clusters that serve as rigid building blocks for constructing frameworks with permanent porosity. In 1999, Yaghi and colleagues used SBU approach to synthesize MOF-5 that consists of zinc oxide clusters and terephthalate linkers. MOF-5 exhibits strong bonds between metal centers and coordinating organic molecules and hence exhibits high thermal stability while maintaining high porosity..
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.